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Summary.-FBJ osteosarcoma virus (FBJ-MSV) isolated originally from a spon-
taneously arising osteosarcoma in a CFI mouse is the only known naturally occurring
murine sarcoma virus (MSV). It is unique among strains of MSV in producing
primarily sarcomata in mice. The capacity of tumour cells transformed in vivo by
this agent to elicit specific transplantation immunity in syngeneic hosts was investi-
gated. A low level of resistance (104-105 cells) was consistently induced by implan-
tation of x-irradiated (15,000 rad) tumours or surgical excision of developing sub-
cutaneous grafts. By contrast intraperitoneal inoculation of virus containing cell
free extracts of FBJ-MSV sarcomata was a far less effective immunization procedure.
Confirmatory evidence for the antigenicity of these neoplasms was obtained in
tests in which preincubation of tumour cells with lymphoid cells from specifically
immune donors inhibited in vivo outgrowth of the FBJ-MSV cells in untreated
syngeneic recipients. The induction of host resistance to FBJ-MSV cells by immu-
nization with identical and independently-induced FBJ-MSV tumours established
that FBJ-MSV cells possess common cell surface antigenic specificities in a manner
analogous to those of experimental neoplasms induced by other oncogenic DNA
and RNA viruses. Since FBJ-MSV cells release infectious virus it was not possible
in this system to establish whether the tumour-rejection antigen was cellular or
virion in nature. The antigenic weakness of FBJ-MSV cells in syngeneic hosts is
comparable with that of virus-induced murine leukaemias of the Gross (G) or
" wild " type subgroup to which category FBJ-MSV also belongs. These features
suggest that FBJ-MSV exemplifies naturally occurring sarcomagenic viruses more
closely than those of the Friend-Moloney-Rauscher-Graffi (FMRGr) subgroup which
in general induce highly antigenic neoplasms.
TuMoUR-associated transplantation
antigens (TATA) have been detected in
all neoplasms transformed by oncogenic
DNA and RNA viruses (Sjogren, 1965;
Klein, 1968; Law, 1969). Similar anti-
genic specificities are demonstrable in all
tumours induced by the same virus,
regardless of the tissue or species of
origin, but not in neoplasms induced by
unrelated viruses. Tumour cells trans-
formed by the oncogenic DNA viruses are
non-permissive, i.e. they do not produce
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infectious virus. The antigens of these
neoplasms are therefore not those of the
mature virion although their continued
presence and resistance to prolonged
negative selection when passaged in pre-
immunized hosts (Sj6gren, 1964) strongly
implicate inheritance of the viral genome
by successive generations of transformed
cells.
The structure of oncogenic RNA
viruses (oncornaviruses) and their mode
of replication differ markedly from theDAVID B. JONES AND MICHAEL MOORE
DNA viruses. In general, virus-trans-
formed cells are permissive, i.e. they
produce infectious virus continuously, a
feature which has complicated attempts
to differentiate between cellular and
virion antigens expressed on neoplastic
cells (Law, 1970).
The most studied tumour antigens of
cells transformed by oncornavirus are
those of the murine leukaemia-sarcoma
virus complex, for which a number of
antigens, principally located on the cell
surface, have been defined using trans-
plantation and serological techniques.
Two major categories of cell surface
antigen are now recognized in association
with infection by murine leukaemia virus
(MLV): (a) the G antigen found in
Passage A (Gross) virus-induced and many
spontaneous leukaemias as well as in
normal tissues of high-leukaemic strains.
(Klein, Sjogren and Klein 1962; Sletten-
mark and Klein, 1962; Old, Boyse and
Stockert, 1965; Aoki, Boyse and Old,
1966); (b) the FMRGr antigen detected
on leukaemic tissues induced by Friend,
Moloney, Rauscher and Graffi viruses
(Old, Boyse and Lilly, 1963; Old, Boyse
and Stockert, 1964; Old and Boyse, 1964;
Glynn, Bianco and Goldin, 1964; Wahren,
1963; Klein and Klein, 1964; Pasternak
and Holzer, 1965).
Sarcomata induced by the recently
isolated variants of MLV described by
Harvey (1964) and Perk and Moloney
(1966) and designated murine sarcoma
virus (MSV) also possess cell surface
antigens but these are indistinguishable
from those expressed on leukaemias of the
FMRGr subgroup (Fefer, McCoy and
Glynn, 1967a; Law, Ting and Stanton,
1968; Chuat et al., 1969; Koldovsky,
Turano and Fadda, 1969; Law and Ting,
1970).
FBJ osteosarcoma virus (hereafter
referred to as FBJ-MSV) was the first
naturally occurring MSV to be isolated
from a spontaneously arising sarcoma
(Finkel, Biskis and Jinkins, 1966). In
marked contrast to other strains of MSV,
this agent induced only sarcomata in
mice (Yumoto et al., 1970; Price, Moore
and Jones, 1972). Serum neutralization
studies established that FBJ-MSV is a
member of the Gross (G+) or "wild "
type as opposed to the FMRGr subgroup
(Kelloff et al., 1969). This feature pro-
vided an opportunity, previously un-
available, for the study of the antigenic
properties of neoplasms induced by a
" wild " type sarcoma virus. In this
paper we describe transplantation experi-
ments demonstrating a common virus-
specified cell surface antigen on FBJ-
MSV transformed cells.
MATERIALS AND METHODS
Animals.-The animals used in this study
were male and female CBAT6T6 and CBA(H)
mice, maintained in our colony by strict
brother-sister mating and tested periodically
for genetic uniformity by skin grafting.
Virus infected mice were routinely isolated
from the main colony.
Tumours.-The origin of the FBJ-MSV
tumour series studied in this paper has been
described previously (Price et al., 1972).
Briefly, 0 05 ml of a Moloney procedure con-
centrate originally provided by Dr R. J.
Huebner (National Cancer Institute, National
Institutes of Health, Bethesda, Maryland,
U.S.A.) diluted 1: 1 in phosphate buffered
saline was injected intramuscularly into the
hind limb of 2 litters of neonatal CBAT6T6
mice. Nine of 15 recipients developed
tumours with latency periods from 27 to 87
days. The cytomorphology ofthese primary
lesions, which were of low grade malignancy,
was mainly that offibrosarcoma. They were
maintained in serial passage by s.c. implan-
tation into syngeneic adult mice of the
appropriate sex.
Virus.-Cell-free extracts of early trans-
plant generations of tumours in this series
were prepared essentially by the method of
Finkel et al. (1966). Freshly excised tumour
was homogenized in 4 volumes of cold
phosphate-buffered saline (pH 7 3) and the
suspension centrifuged at 3000 rev/min. The
supernatant was decanted, recentrifuged at
10,000 rev/min andfilteredthrough a0-45 ,um
HA type Millipore filter and stored in liquid
nitrogen untilrequired.
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For the induction of new primary neo-
plasms, neonatal CBA(H) or AKR mice,
which exhibit a comparable susceptibility to
FBJ-MSV (Kelloff et al., 1969), received a
single s.c. injection (0-1 ml) ofcell-free extract
into the leftthigh.
For immunization, adult CBA(H) mice
received a series of i.p. injections (0 5 ml) of
cell-free virus preparations the oncogenicity
of which had been confirmed previously in
newborn AKR mice.
Induction oftumour immunity
Three procedures were used for studying
the immunogenicity of FBJ-MSV induced
sarcomata passaged in syngeneic hosts:
(a) Implantation of irradiated tumour iso-
grafts.-Tumour grafts (approximately
4 mm x 4 mm diameter) in Eagles' minimal
essential medium (Eagles' MEM) were ex-
posed to 15,000 rad x-irradiation delivered
at the rate of 375 rad/min from a Westing-
house x-ray therapy set operating at 220 kV.
and 14 mA with 1 mm Cu and 1 mm Al
filtration (Moore and Williams, 1972). The
irradiated grafts were immediately implan-
ted subcutaneously and bilaterally into adult
mice of the appropriate sex. All experi-
mental groups received 4 such immunizations
at approximately 10-day intervals; (b) Excis-
ion of subcutaneous tumour grafts.-Viable
4 mm diameter tumour grafts were unilater-
ally implanted subcutaneously into 10-week
old CBA(H) mice of the appropriate sex.
The grafts were cleanly excised when they
reached a diameter of 10 mm; (c) Intra-
peritoneal inoculation ofvirus.-Experimental
groups of adult CBA(H) mice received 4-6
intraperitoneal injections at 10-day intervals
before challenge. Before use for immuniza-
tion, the oncogenicity ofeach cell-free prepar-
ation ofFBJ-MSV was confirmedbyrecording
tumour incidences in neonatally-injected
AKR mice.
Tumour cell challenge
In all cases challenge inocula of viable
tumour cells were given 10 days after the
last immunization, or following tumour
excision. Tumour cell suspensions were
obtained by enzymatic digestion of fresh,
minced tumour material at 37°C in 0.25%
trypsin (Biocult Laboratories, Paisley, Scot-
land) or 0 25% collagenase (Sigma Chemical
Co.,Kingston-upon-Thames, Surrey)inHank's
balanced salt solution. The latter enzyme
was used preferentially as for most FBJ-MSV
tumours viable cells were freed from inter-
cellular matrix with greater facility than with
trypsin.
Cells were washed once by centrifugation
in serum-free Eagles' MEM and the viable
cells enumerated by trypan blue exclusion.
Challenge inocula were injected in 0-1 ml
of serum-free medium subcutaneously into
the left flank. Test and control groups
received 400 rad whole body irradiation
(33 5 rad/min) 24 hours before challenge.
This procedure depressed the primary
response of both groups to the challenge
inoculum, without appreciably affecting the
secondary response in previously immunized
individuals, thereby permitting the detection
of weak levels of host resistance and mini-
mizing nonspecific effects (Sj6gren, 1965;
Globerson and Feldman, 1964). All mice
were palpated weekly for evidence of tumour
outgrowth.
Neutralization of viable tumour cell inocula
Adult CBA(H) mice received weekly
intraperitoneal immunizations with 2 x 106
x-irradiated (15,000 rad) FBJ-MSV sarcoma
cells in Eagles' MEM. Effector cells were
obtained 6 days following the last of at
least 3 immunizations. Three days before
harvesting, mice received 0 5 ml of a 10%
(w/v) suspension of hydrolysed starch in
Eagles' MEM. Control non-immune mice
were treated similarly.
Peritoneal cells were obtained by lavage
with 1% (v/v) unpreserved heparin (Boots
Pure Drug Co., Nottingham) in Eagles'
MEM. Cells were maintained at 4°C and
washed twice by centrifugation in serum-free
medium. Generally, cells were pooled from
a minimum of 3 mice. Spleens from normal
and hyperimmune mice were homogenized
and filtered in cold Eagles' MEM and
similarlywashed.
Nucleated cells were counted and adjusted
to 1 X 107 cells/ml. One-ml aliquots of
this suspension were then admixed with 1 ml
of Eagles' medium containing 5 x 105 FBJ-
MSV sarcoma target cells, to give a final
effector cell: target cell ratio of 20: 1.
Standard aliquots (0f2 ml) of this suspension
were then promptly inoculated subcutan-
eously into recipient syngeneic adult mice
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which had received 400 rad whole body
x-irradiation 24 hours previously. The final
concentration of target cells for each mouse
was 5 x 104 and of effector cells, 1 X 106.
Recipients were palpated weekly for evidence
oftumour development atthe siteofinjection.
RESULTS
(a) Response to irradiated syngeneic tumour
grafts
The immune response evoked by
FBJ-MSV induced sarcomata following
repeated implantation of irradiated
(15,000 rad) tumour grafts was deter-
mined by comparison oftumour incidences
in immunized hosts with untreated con-
trols. On this criterion, in a series of
24 tests with 9 different tumours, 8
evoked resistance to their own trans-
plantation in syngeneic recipients (Table
I). In quantitative terms, the challenge
inocula at which final tumour incidences
in immune and non-immune groups were
significantly different were usually greater
than 5 x 103 cells but exceeded 105 cells in
only one instance (FBJ 5). In other
tests (with FBJ 3 and FBJ 7) conducted
at this challenge inoculum, tumour out-
growth in both pretreated mice and
untreated controls was 100%, although
the rate of tumour development was
occasionally retarded. However, there
was rarely any difference in the time of
appearance of palpable neoplasms (latent
period) in test and control groups even
at the lower challenge inocula.
With the exception of FBJ 9, to which
immunity could not be demonstrated,
the level ofresistance induced by tumours
in this series was uniform and of the order
of 1-2 logarithmic units greater than the
minimum inoculum of cells required to
produce tumour in the majority of un-
treated syngeneic recipients.
The cross-reactivity of antigenic FBJ-
MSV induced sarcomata in syngeneic
hosts was studied in a further 15 trans-
plantation tests involving different com-
binations of tumours. In 11/12 of such
TABLE I.-Induction of Host Resistance by Irradiated Isografts ofFBJ-MSV
Induced Murine Sarcomata
Immunizing tumour
and transplant
generation*
FBJ 1/11-1/12
FBJ 1/11-1/12
FBJ 1/10-1/12
FBJ 1/6-1/8
FBJ 2/5-2/7
FBJ 2/4-2/5
FBJ 3/2-3/4
FBJ 3/5-3/6
FBJ 3/3-3/4
FBJ 3/5-3/6
FBJ 4/7-4/9
FBJ 5/3-5/4
FBJ 5/4-5/6
FBJ 6/4-6/7
FBJ 6/4-6/5
FBJ 7/2-7/4
FBJ 7/6-7/7
FBJ 7/2-7/3
FBJ 7/3-7/5
FBJ 7/3-7/5
FBJ 9/8-9/9
FBJ 9/8-9/9
FBJ 9/3-9/5
FBJ 16/3-16/5
Challenge tumour
and transplant
generation
FBJ 1/13
FBJ 1/14
FBJ 1/12
FBJ 1/8
FBJ 2/8
FBJ 2/6
FBJ 3/5
FBJ 3/7
FBJ 3/6
FBJ 3/7
FBJ 4/10
FBJ 5/4
FBJ 5/7
FBJ 6/8
FBJ 6/6
FBJ 7/5
FBJ 7/7
FBJ 7/4
FBJ 7/6
FBJ 7/6
FBJ 9/10
FBJ 9/10
FBJ 9/6
FBJ 16/6
Tumour outgrowth in
I
Challenge
doset
5 x 104
1 X 104
1 X 104
1 X 103
1 X 103
1 X 104
1 x 105
1 X 104
5x 103
1 X 103
1 X 104
1 x 105
1 x 104
1 X 104
1 X 104
1 x 105
1 x 105
1 X 104
5 x 103
1 X 103
1 X 104
1 X 103
1 X 103
1 X 104
Treated
mice
2/6
1/6
2/8
0/9
2/10
2/7
9/9
4/10
2/10
0/10
2/9
5/9
2/7
5/10
4/8
8/8
1/8
1/4
2/10
0/4
7/7
2/8
0/9
1/5
Latent
period:
21
42
30
30
30
18
17
23
32
19
20
20
20
40
37
32
14
20
40
27
Untreated
controls
5/6
3/10
5/5
2/9
4/10.
7/10
8/8
8/8
7/9
1/8
7/9
5/5
5/7
8/10
8/8
9/9
5/5
7/7
5/9
0/10
5/6
1/7
0/9
4/5
Latent
period:
21
30
30
45
30
30
18
31
23
40
32
19
20
20
20
40
37
32
14
20
40
27
* Mice received 4 bilateral implantations of x-irradiated (15,000 rad) tumour at 10-day intervals.
t Mice received 400 rad x-irradiation 24 hours before challenge.
I Time in days to first palpable tumour.
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TABLE II.-Induction of Host Resistance to FBJ-MSV Sarcoma Cells by
Immunization with Identical and Independently-induced FBJ-MSV Tumours
Immunizing tumour
and transplant
generation*
FBJ 2/11-2/12
FBJ 2/4-2/5
FBJ 3/9-3/11
FBJ 3/5-3/6
FBJ 3/9-3/11
FBJ 3/3-3/4
FBJ 4/2-4/4
FBJ 4/7-4/9
FBJ 4/9-4/7
FBJ 6/6-6/7
FBJ 6/10-6/12
FBJ 6/6-6/7
FBJ 6/4-6/7
FBJ 7/9-7/10
FBJ 7/9-7/10
FBJ 7/10-7/12
FBJ 7/10-7/12
FBJ 7/2-7/3
FBJ 7/10-7/12
FBJ 7/10-7/12
FBJ 7/10-7/12
Challenge tumour
and transplant
generation
FBJ 4/9
FBJ 2/6
FBJ 7/8
FBJ 3/7
FBJ 7/8
FBJ 3/6
FBJ 2/4
FBJ 4/10
FBJ 10/9
FBJ 3/8
FBJ 4/10
FBJ 4/10
FBJ 6/8
FBJ 1/11
FBJ 3/11
FBJ 4/9
FBJ 4/9
FBJ 7/4
FBJ 19/6
FBJ 2/12
FBJ 6/10
Tumour outgrowth in
, K 5~~~
Challenge
doset
1 X 104
1 X 104
1 X 104
1 X 104
5X 103
5X 103
1 X 104
1 X 104
1 X 104
1 X 104
2X 104
1 X 104
1 X 104
1 X 104
1 X 104
1 X 104
1 X 104
1 X 104
2x 104
1 X 104
1 X 104
Treated
mice
4/9
2/7
4/5
4/10
2/5
2/10
5/9
2/9
0/5
2/5
4/9
0/7
5/10
0/5
2/6
1/6
1/5
1/4
2/5
3/8
4/9
Latent
periodt
30
30
27
17
27
23
25
32
20
24
24
20
20
16
21
21
32
27
30
23
Untreated
controls
9/10
7/10
5/5
8/8
5/5
7/9
10/10
7/9
4/9
7/10
5/5
8/10
8/10
4/9 5/7
5/5
6/10
7/7
4/5
7/8
9/9
Latent
period:
26
30
27
17
27
23
25
32
30
20
24
24
20
20
16
21
21
32
27
30
23
* Mice raceived 4 bilatoral implantations of x-irradiated (15,000 rad) tumour at 10-day intervals.
t Mice received, 400 rad x-irradiation 24 hours before challenge. I Time in days to first palpable tumour.
combinations, immunity was induced by
5 FBJ tumours against challenge with
7 different FBJ sarcomata (Table II).
Quantitatively, the resistance induced was
comparable with that obtained in mice
immunized and challenged with identical
tumours. In only one example, where
mice were immunized with FBJ 3 and
challenged with FBJ 7, were differences
in tumour incidences in test and control
groups insignificant.
To establish the specificity of these
cross-reacting antigeps for sarcomata in-
duced by FBJ-MSV, and to eliminate the
possibility that resistance was due to a
nonspecific increase in immune respon-
siveness, mice variously received irradia-
ted grafts of normal syngeneic and allo-
geneic tissues or of syngeneic sarcomata
of putatively nonviral origin (Table III),
known from comparable transplantation
tests to possess TSTA. Thereafter they
were challenged with FBJ-MSV tumours
at inocula comparable with those at which
resistance to the latter was consist-
ently induced. In 11 experiments in which
mice were pretreated with normal syn-
geneic or allogeneic tissues and challenged
with 5 different FBJ-MSV sarcomata,
neither resistance nor a significant delay
in tumour outgrowth could be demon-
strated. Similar inability to protect
against challenge with FBJ-MSV sar-
coma cells was demonstrated for 3 anti-
genically distinctive sarcomata (MCB2,
MCB3 and S115), an observation which
was confirmed in a reciprocal test where
preimmunization with FBJ 7 failed to
protect against challenge with S115,
a weakly antigenic radiation-induced
osteosarcoma (Moore and Williams,
1972).
(b) Response to tumour excision
The immune response evoked by
FBJ-MSV induced sarcomata was also
determined by excision of subcutaneously
developing tumour grafts. By previously
established criteria of tumour resistance.
in a series of 8 tests 7 tumours exhibited
significant immunogenicity. Tumour in-
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TABLE III.-Specificity of Host Resistance Induced by Irradiated Isografts of
FJB-MSV Induced Murine Sarcomata
Immunizing tumour
and transplant
generation*
FBJ 2/4-2/5
MCB 3/5-3/9
CBA(H)
Normal tissue
FBJ 7/6-7/8
MCA 2/4-2/6
CBA (H)
Normal tissue
FBJ 7/5-7/8
S115/16-S115/18
CBA (H)
Normal tissue
FBJ 1/10-1/12
CBA(H)
Normal tissue
FBJ 7/2-7/3
CBA(H)
Normal tissue
FBJ 7/3-7/5
CBA(H)
Normal tissue
FBJ 3/5-3/6
BALB/c
Normal tissue
CBA(H)
Normal tissue
FBJ 7/2-7/3
BALB/c
Normal tissue
CBA(H)
Normal tissue
FBJ 7/2-7/3
Challenge tumour
and transplant
generation
FBJ 2/7
FBJ 2/7
FBJ 2/7
FBJ 7/9
FBJ 7/9
FBJ 7/10
S 115/14
FBJ 6/6
Tumour outgrowth in
, A A~~~~~~~~~'
Challenge
doset
1 X 104
1 X 104
Treated Latent
mice period:
1/6 30
11/11 32
X 104 8/10 30
1X104 1/5 30
1x104 9/9 30
1 X 104
1 X 103
5 x 103
10/10
9/9
9/9
30
17
21
Untreated
controls
7/10
7/7
Latent
period$
30
32
8/10 30
7/7 30
8/9 30
8/8
7/8
6/6
30
17
21
FBJ 1/10 I x 104 6/9 42 6/10 42
FBJ 1/12 1 x 104 1/10 42 4/10 30
FBJ 7/11 1 x 104 5/5 26 5/5 26
FBJ 7/4 1 x 104 1/4 32 7/7 32
FBJ 7/11 5x 103 5/6 30 5/7 30
FBJ 7/6 5x 103 2/10 14 5/9 14
FBJ 3/10 1 x 104 8/10 21 8/10 21
FBJ 3/7 1 x 104 4/10 17 8/8 17
FBJ 7/10 1 x 104 9/9 25 5/6 25
FBJ 7/10 1 x 104 4/5 25 5/5 25
FBJ 7/4 1 x 104 1/4 32 7/2 32
FBJ 6/10 1 x 104 6/6 21 6/6 21
FBJ 6/10 1 x 104 6/6 21 6/6 21
FBJ 6/8 1x 104 5/10 20 8/10 20
MCA2-Methylcholanthrene-induced sarcoma in C3H mouse.
MCB3-Methylcholanthrene-induced sarcoma in CBA(H) mouse.
S15 Radiation induced sarcoma in CBA(H) mouse.
* Mice received 4 bilateral implantations of x-irradiated (15,000 rad) tumour at 10-day intervals.
t Mice received 400 rad x-irradiation 24 hours before challenge.
t Time in days to first palpable tumour.
cidences following challenge with 104 cells
in mice previously exposed to a growing
neoplasm were invariably lower than in
non-immune controls (Table IV). Tumour
outgrowth in mice immunized by this
procedure did not differ significantly
from that observed following immuniza-
tion with irradiated isografts nor was
there any apparent difference in the level
ofhost resistance (Tables I and II).
Antigenic cross-reactivity of the FBJ-
MSV sarcomata was again demonstrated
by this technique. Thus, in 4 indepen-
dent tests in which mice immunized with
5 FBJ-MSV tumours werecross-challenged
with 3 different sarcomata, resistance was
readily demonstrable.
In a further 4 experiments mice
subjected to mock excision or from which
developing syngeneic embryonic tissue
was excised did not prove resistant to
challenge with 2 FBJ-MSV tumours.
Excision of an antigenically unrelated
neoplasm (MCB 2) likewise failed to pro-
tect. Consistent with results obtained
by the method of immunization with
irradiated tumour grafts, these experi-
ments underlined the specificity of the
immune response to FBJ-MSV induced
sarcomata.
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TABLE IV.-Host Resistance Following Excision ofSubcutaneous Transplants
of Murine Sarcomata Induced by FBJ-MSV
Immunizing tumour
and transplant
generation*
FBJ 1/13
FBJ 1/13
FBJ 2/4
FBJ 2/4
FBJ 3/9
FBJ 4/2
FBJ 4/6
FBJ 5/6
FBJ 6/14
FBJ 7/10
FBJ 7/10
FBJ 7/10
Mock excision
Mock excision
Syngeneic
embryoma
MCB 2/4
Challenge tumour
and transplant
generation
FBJ 1/13
FBJ 4/10
FBJ 2/6
FBJ 7/10
FBJ 3/9
FBJ 4/3
FBJ 5/6
FBJ 7/10
FBJ 6/14
FBJ 7/10
FBJ 7/10
FBJ 5/6
FBJ 2/6
FBJ 7/10
Tumour outgrowth in
A
Challenge
doset
1 X 104
1 X 104
1 X 104
1 X 104
1 X 104
1 X 104
1 x 105
1 X 104
1 X 104
1 X 104
1 X 104
1 x 105
1 X 104
1 X 104
Treated
mice
1/7
1/6
2/7
2/6
3/5
1/6
6/9
2/7
4/8
2/5
4/9
5/8
5/6
6/6
Latent Untreated Latent
period: controls period:
29 7/8 29
34 6/8 34
34 7/10 34
40 10/10 40
42 6/6 42
37 8/10 37
22 8/8 22
36 9/10 36
40 10/10 40
31 10/10 31
33 9/10 33
21 8/9 21
29 6/6 29
32 6/6 32
FBJ 7/10 1 x 104 8/8 37 8/8 37
FBJ 7/9 1 x 104 8/8 30 8/8 30
MCB2-Methylcholanthrene induced sarcoma in CBA(H) mouse.
* Mice received four bilateral implantations of x-irradiated (15,000 rad) tumour at 10-day intervals.
t Mice received 400 rad pre-irradiation 24 hours before challenge.
I Time in days to first palpable tumour.
(c) Response to cell-free preparations of
FBJ-MSV
The ability of repeated intraperitoneal
immunization with cell-free preparations
of known oncogenic potential from FBJ
virus-induced sarcomata to protect against
outgrowth of viable syngeneic tumour
cell inocula was assayed in 6 experiments
involving challenge with viable cells from
3 FBJ sarcomata and at inocula of 5 x 103
and 104 cells (Table V).
Ofthese 6 groups, 4 showed a marginal
reduction in takes by comparison with
untreated controls at both challenge
inocula and one demonstrated apparent
enhancement of tumour outgrowth. In
the remaining group no growth inhibition
was observed as a result of preimmuniza-
tion with cell-free FBJ-MSV tumour
preparations. The time at which tumours
were first palpable (latent period) did
not differ in pre-treated and untreated
mice.
These experiments underlined the rela-
tive inefficiency of cell-free extracts of
FBJ-MSV sarcomata to induce immunity
compared with procedures involving ex-
posure of the host to intact tumour
cells.
TABLE V.-Host Resistance Following Intraperitoneal Inoculation of Oncogenic
Cell-free Preparations ofFBJ-MSV
Challenge
tumour and
transplant
generation
FBJ 7/11
FBJ 7/11
FBJ 7/14
FBJ 3/10
FBJ 3/13
FBJ 2/12
Tumour outgrowth in
Primary tumour incidence
Challenge Treated Latent Untreated Latent in neonates injected with
dose* mice period: controls period: immunizing preparation§
104 8/8 30 8/9 30 1/5
104 3/5 27 4/5 27 3/7
5X103 1/4 27 3/5 27 2/6
104 3/5 27 4/4 27 4/8
5x103 5/6 32 3/6 32 2/7
5X103 1/5 26 3/5 26 I
* Mice received 400 rad x-irradiation 24 hours before challenge.
t Mice received i.p. injections (0-5 ml) of cell-free extract at 10-day intervals.
$ Time in days to first palpable tumour.
§ Fraction of AKR mice yielding sarcomata within 90 days of injection as newborns with 0.1 ml of im-
munizing virus preparation.
No. of
injections
of FBJ-MSVt
6
6
5
4
5
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(d) Neutralization of viable FBJ-MISV
tumour cells
The capacity of cell preparations
obtained from the peritoneal cavity and
spleen of hyperimmunized mice to effect
a reduction in tumour incidence when
admixed with viable tumour cells was
assayed in 19 experiments (Table VI).
Spleen and peritoneal exudate cells
from 8 pre-immunized donors were tested
in various combinations against 5 FBJ-
MSV sarcoma cell suspensions at a con-
stant effector cell: target cell ratio of
20: 1. In all but one example (FBJ 13)
when target cells alone were injected
subcutaneously into pre-irradiated (400
rad) recipient mice, tumour outgrowth
occurred in all animals. Suppression of
tumour growth was sometimes observed
with peritoneal exudate and spleen cell
populations from normal mice or mice
immunized against an antigenically un-
related tumour (MCB 2). However, the
percentage reduction in tumour takes
over tumour cells alone in these instances
did not exceed 25%. By contrast, spleen
and peritoneal exudate cells from mice
pre-immunized against FBJ-MSV sarcoma
cells consistently reduced the number of
tumour takes in pre-irradiated recipients.
This effect was observed regardless of
whether effector cells were derived from
mice immunized with the same FBJ-MSV
tumour as the target cell or from mice
immune to different FBJ-MSV induced
sarcomata.
No significant differences wereobserved
in the time of appeatance of first pal-
pable tumours (latent period) in groups
which received tumour cells alone, or
tumour target cells admixed with effector
cells from previously immunized mice or
their normal untreated counterparts.
DISCUSSION
In studies on the immunology of
tumour cells transformed by the murine
sarcoma viruses (MSV), most attention
to date has focussed on sarcomata in-
duced by MSV-M (Moloney) and MSV-H
(Harvey), both of which belong to the
FMRGr subgroup of oncornavirus type
specificity (Fefer et al., 1967a; Chuat et al.,
1969). These viruses rapidly induce neo-
plastic and non-neoplastic lesions in a
variety of host species (Harvey and East,
1971). The absence of such non-neo-
plastic conditions in association with the
host-virus interaction in mice infected
with FBJ-MSV (Finkel et al., 1966; Price
et al., 1972) and the wild-type antigenic
specificity (Kelloff et al., 1969) distinguish
FBJ-MSV induced sarcomata from those
induced by MSV isolates of the FMRGr
subgroup and justify investigation of the
immunological properties of this tumour-
host system.
In common with experimental neo-
plasms induced by oncogenic DNA and
RNA viruses, tumour cells transformed
in vivo by FBJ-MSV possess cell surface
antigens capable of evoking tumour rejec-
tion responses in syngeneic hosts. Specific
resistance to transplanted inocula of
FBJ-MSV sarcoma cells could be built
up by pretreatment of adult hosts with
x-irradiated tumour cells or by excision
of subcutaneously developing tumour
grafts. The ability of lymphoid cell
populations from specifically immune don-
ors to inhibit outgrowth in vivo of FBJ-
MSV sarcoma cells transplanted to syn-
geneic recipients provided additional evi-
dence for the antigenicity of these
neoplasms. Furthermore, the induction
of transplantation resistance is paralleled
by the appearance of humoral antibodies
in the serum of immunized mice reactive
with cell-surface antigens of FBJ-MSV
cells and detectable by indirect immuno-
fluorescence tests on viable cell suspen-
sions (to be published).
Transplantation tests involving im-
munization and challenge with indepen-
dently induced FBJ-MSV sarcomata es-
tablished that these tumours possess
overlapping antigenic specificities com-
parable with those shared by other
virus-induced neoplasms. Similar results
were obtained by neutralization tests
utilizing FBJ-MSV target cells and lym-
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TABLE VI.-Inhibition of Outgrowth ofFBJ-MSV Sarcoma Cells in vivo
Following in vitro Incubation with Lymphoid Cellsfrom Immune Donors
Source of
effector cells
FBJ 1 immune
Normal
FBJ 1 immune
Normal
FBJ 7/11 immune
Normal donor
MCB-2t immune
FBJ 711 immune
FBJ 2/14 immune
Normal donor
FBJ 7/11 immune
FBJ 2/14 immune
Normal donor
FBJ 13/9 immune
Normal donor
FBJ 13/9 immune
Normal donor
FBJ 11/7 immune
Normal donor
FBJ 11/7 immune
Normal donor
FBJ 19/6 immune
Normal donor
FBJ 13/10 immune
MCB-2 immune
FBJ 21/6 immune
Normal donor
FBJ 21/6 immune
Normal donor
Effector
cell type
Spleen
Spleen
Peritoneal exudate
Peritoneal exudate
Peritoneal exudate
Peritoneal exudate
Peritoneal exudate
Peritoneal exudate
Peritoneal exudate
Peritoneal exudate
Spleen
Spleen
Spleen
Spleen
Spleen
Peritoneal exudate
Peritoneal exudate
Spleen
Spleen
Peritoneal exudate
Peritoneal exudate
Spleen
Spleen
Spleen
Spleen
Peritoneal exudate
Peritoneal exudate
Spleen
Spleen
* Effector cell: target cell ratio 20 :1 in all cases.
t MCB-2 methylcholanthrene induced sarcoma.
t Standard target cell inoculum 5 x 104 cells.
phoid cells from hosts immunized against
different FBJ-MSV induced sarcomata.
These specificities were not present on
normal adult host tissues of the CBA(H)
strain, on certain allogeneic tissues, nor
on murine sarcomata induced by other
aetiological agents, e.g. chemical carcino-
gens and radiation. In respect of anti-
genicity in syngeneic hosts, tumours
induced by FBJ-MSV are thus similar to
those transformed by MSV isolates inclu-
dingMSV-H (Chuatetal., 1969; Koldovsky
et al., 1969) MSV-M (Fefer et al., 1967a, b,
c; 1968; Law et al., 1968; Stanton, Law
and Ting, 1968) and MSV-K (Kirsten)
(McCoy etal., 1972).
Targot*
cell
FBJ 4/7
FBJ 4/7
FBJ 4/7
FBJ 4/7
FBJ 4/7
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 7/12
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 13/9
FBJ 19/6
FBJ 19/6
FBJ 19/6
FBJ 19/6
FBJ 19/6
FBJ 21/7
FBJ 21/7
FBJ 21/7
FBJ 21/7
FBJ 21/7
Tumour
outgrowth
in group
1/5
4/5 4/5
4/4
4/4
1/5
4/5
4/5
5/5
3/5
3/5
5/5
2/5
2/5
5/5
0/4
3/5
2/5
4/5
0/4
3/5
1/5
4/5
4/5
3/5
5/5
2/5
4/5
5/5
3/5
4/5
1/5
4/5
5/5
% Inhibition
ofoutgrowth
in vivo over
target cells
alonet
80
20
20
0
80
20
20
40
40
0
60
60
0
100
25
50
0
100
25
75
0
40
0
60
20
40
20
80
20
The nature of the FBJ-MSV tumour-
rejection antigen(s) cannot be elucidated
at present. Transplantation methodology
as employed in this investigation is
incapable of establishing whether the
rejection phenomenon in this tumour-
host system is mediated primarily by new
virus-determined cellular antigens or, since
FBJ-MSV cells release infectious virus,
by components of the viral capsid incor-
porated into the cell surface membrane.
Among neoplasms of the murine leuk-
aemia-sarcoma virus complex, the pres-
ence of mature virions in tumours has
complicated attempts to discriminate
between cellular and virion antigens
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expressed by transformed cells. The co-
existence of lesions such as atypical
granulomata, erythroblastic splenomegaly
and disseminated cystic lesions among
MSV isolates of the FMRGr subgroup are
indicative of host-virus interactions addi-
tional to the process of neoplastic trans-
formation (Harvey and East, 1971).
Within these systems, immunization with
cell-free virus preparations is effective in
protecting against challenge with tumour
cell inocula (Chuat et al., 1969; Koldovsky
et al., 1969; Fink and Rauscher, 1964;
Kobayashi and Takeda, 1967) and it
appears that the rejection response is
mediated principally by viral antigens
present on the cell surface (Law, 1970).
This conclusion is supported by the
induction of transplantation resistance
to MSV-M sarcomata by MSV-M induced
lesions which are not strictly neoplastic
tissues and by the passive transfer of
immunity by anti-MSV antibody (Law
etal., 1968).
In this study immunization with
intact FBJ-MSV transformed cells was
a far more effective and reliable procedure
for inducing immunity than repeated
inoculation of adults with virus-contain-
ing cell free extracts. This might imply
that integrity of cell surface structure is
obligatory for consistent immunogenicity
and suggest that the rejectionphenomenon
is mediated by a new cell surface antigen
either not identifiable as FBJ-MSV itself
or present in a modified form, although
other explanations are clearly possible.
The demonstration of tumour rejection
antigens distinct from virion antigens on
the surface of virus-transformed cells
was claimed by Ting (1967) for a neoplasm
(MSB-1) of epithelial cell origin in the
rat induced by MSV; and by Law and
Ting (1970) for a transplantable murine
haemangiosarcoma (XM-1) induced by
MSV. However, the former cell line
was subsequently found to release both
a focus forming virus (MSV-0) (Ting,
1968) and a rat-tropic helper leukaemia
virus (Aaronson, 1971) while the latter
also produces C-type virus particles.
By contrast, Stephenson and Aaronson
(1972) showedthatMSV-transformedBalb/
3T3 non-producer cells lack detectable
transplantation antigens and suggest that
transplantation resistance to the produ-
cing cells is attributable to maturing
virus at the cell surface.
The problem of the nature of the
FBJ-MSV tumour rejection antigen is,
however, further complicated by the fact
that, in common with other RNA mem-
bers of the murine oncogenic leukaemia-
sarcoma virus complex, FBJ-MSV is
found associated with a non-pathogenic
virus (FBJ-MLV) at high titre (Levy,
Hartley and Huebner, 1973). At present
it is not known if this virus is a non-
pathogenic murine leukaemia virus, a
non-pathogenic mutant of FBJ-MSV, or
whether FBJ-MLV rescued a sarcoma
genome from an original CF-I sarcoma
cell and returned FBJ-MSV to an infec-
tious state. Analogous studies on neo-
plasms ofthe leukaemia-sarcoma complex
in the FMRGr subgroup, where the
associated leukaemia viruses are patho-
genic and function as helpers for the
production of infectious MSV, have failed
to reveal differences in antigenic specificity
in cells transformed by MSV and MLV
(Fefer et al., 1967a; Chuat et al., 1969;
Strouk et al., 1972). A similar situation
might be found to pertain for cells trans-
formed by viruses of the FBJ MSV/MLV
complex.
The maximum level of resistance
induced by FBJ-MSV cells in syngeneic
hosts did not exceed 105 cells, i.e. the
antigenicity of these neoplasms is of a
relatively weak order compared with
murine sarcomata induced by classic
chemical carcinogens (Klein et al., 1960).
It is noteworthy that in this respect
FBJ-MSV induced neoplasms are com-
parable with spontaneous murine neo-
plasms (Prehn and Main, 1957; Hammond,
Fisher and Rolley, 1967) and with virus
induced murine leukaemias of the Gross
(G) or "wild " type subgroup (Klein
et al., 1962; Stettenmark and Klein, 1962)
as opposed to leukaemias and sarcomata
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of the FMRGr subgroups which are much
more strongly antigenic (Klein and Klein,
1964; Fefer et al., 1967a). This antigenic
weakness on the part of the naturally
occurring leukaemia-sarcoma viruses, to-
gether with the findings on the natural
occurrence of Gross virus and the specific
cellular antigen (G) determined by it
(Old, Boyse and Stockert, 1965; Aoki
et al., 1966), suggest that the agents may
reflect a multivalent virus having a differ-
ent potential in different host cells or a
heterogeneous population of pathogenic
and non-pathogenic variants present in
nature. By contrast, this situation is
not necessarily true of some of the other
viral agents of the FMRGr subgroup
which were isolated from serially trans-
planted neoplasms in the laboratory
and which induce highly antigenic neo-
plasms less likely to occur under natural
circumstances.
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